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Cyclosporine, a drug used in immunosuppression protocols for hematopoietic stem cell
transplantation that has a narrow therapeutic index, may cause various adverse reactions,
including nephrotoxicity. This has a direct clinical impact on the patient. This study aims
to  summarize available evidence in the scientiﬁc literature on the use of cyclosporine in
respect to its risk factor for the development of nephrotoxicity in patients submitted to
hematopoietic stem cell transplantation. A systematic review was made with the follow-
ing  electronic databases: PubMed, Web of Science, Embase, Scopus, CINAHL, LILACS, SciELO
and  Cochrane BVS. The keywords used were: “bone marrow transplantation” OR “stem cell
transplantation” OR “grafting, bone marrow” AND cyclosporine OR cyclosporin OR “risk fac-
tors” AND “acute kidney injury” OR “acute kidney injuries” OR “acute renal failure” OR “acute
renal failures” OR “nephrotoxicity”. The level of scientiﬁc evidence of the studies was clas-
siﬁed according to the Oxford Centre for Evidence Based Medicine. The ﬁnal sample was
composed of 19 studies, most of which (89.5%) had an observational design, evidence level
2B  and pointed to an incidence of nephrotoxicity above 30%. The available evidence, con-
sidered as good quality and appropriate for the analyzed event, indicates that cyclosporine
represents a risk factor for the occurrence of nephrotoxicity, particularly when combined
with amphotericin B or aminoglycosides, agents commonly used in hematopoietic stem cell
transplantation recipients.© 2014 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Publishedntroductionyclosporine is an essential drug in the therapeutic regimen
f allogeneic hematopoietic stem cell transplantation (HSCT)
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recipients. It mainly acts on T cells, suppressing their acti-
vation and decreasing the release of lymphokines.1,2 On theidade Estadual de Campinas – UNICAMP, 13084-971 Campinas, SP,
other hand, cyclosporine administration demands systematic
and regular serum level monitoring as, being a substrate of
the cytochrome P450 enzyme system, it presents a narrow
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
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therapeutic index and is involved in drug interactions and rel-
evant adverse reactions.3,4 The addition and/or interruption of
other co-administered drugs may affect cyclosporine serum
levels, since they may suppress or induce the cyclosporine
metabolism or the metabolism of its metabolites, possibly
causing ineffective therapy or increased toxicity, particularly
nephrotoxicity.5
Although the epidemiology of nephrotoxicity in HSCT
varies widely (from 14% to 73%), it is important due to the
clinic impact of the resulting adverse effects.6–8 The varia-
tion in incidence can be explained by differences between
studies regarding patient follow-up, type of conditioning reg-
imen, the presence of hypertension prior to HSCT, hepatic
sinusoidal obstruction syndrome, amphotericin B usage and
other nephrotoxic drugs, as well as the differences in the
criteria used for the deﬁnition of nephrotoxicity.9–11 However,
independent of risk factors, nephrotoxicity affects HSCT recip-
ients, worsening their clinical condition.
Studies have shown that the nephrotoxicity in HSCT recip-
ients represents a relevant risk factor for the development of
chronic kidney injury. It has been associated with increases
in both short-term and long-term mortality and may affect
around 70% of patients.6,10 Considering the importance of
cyclosporine for the success of HSCT, its nephrotoxic potential
and the lack of studies that address this research question, the
purpose of the current study was to accumulate the evidence
available in the scientiﬁc literature about cyclosporine usage
as a risk factor for the development of nephrotoxicity in HSCT
recipients.
Method
A search for articles was performed with the following elec-
tronic databases: PubMed, Web of Science, Embase, Scopus,
CINAHL, LILACS, SciELO and Cochrane BVS, without lim-
its on time. Keyword selection was based on the PICO12
strategy. Thus, the included keywords were “bone marrow
transplantation” OR “stem cell transplantation” OR “graft-
ing, bone marrow” for patient (P) AND “cyclosporine” OR
“cyclosporin” OR “risk factors” for intervention (I) AND “acute
kidney injury” OR “acute kidney injuries” OR “acute renal fail-
ure” OR “acute renal failures” OR “nephrotoxicity” for outcome
(O).
The inclusion criteria of the study were: articles published
in Portuguese, English or Spanish, with summaries available
in databases, which referenced cyclosporine usage and nep-
hrotoxicity in HSCT recipients. Studies concerning pediatric
populations, editorials, letters and reviews were excluded. The
systematic review was completed in December 2012.
Articles were selected by two authors separately and,
in case of disagreement, a third author reviewed them to
decide about inclusion. Upon searching, countless terms were
observed related to nephrotoxicity, such as kidney toxicity,
kidney dysfunction, acute renal failure (ARF) and acute kid-
ney injury (AKI). In spite of AKI being the most commonly
used term in recent studies, in this systematic review the term
“nephrotoxicity” was considered more  appropriate to analyze
adverse drug events. 2 0 1 4;3  6(5):363–368
At the outset, 746 articles were found that were trans-
ferred to Endnote® Web.13 This program identiﬁed 184
duplicate articles, with 562 publications remaining. After
reading the titles and abstracts, 518 articles were excluded.
The remaining 44 articles were evaluated by reading in
full and another 25 were excluded for the following rea-
sons: two were histological studies and cyclosporine was not
investigated as an independent variable of probable risk fac-
tor for nephrotoxicity in HSCT recipients in the other 23
articles.
Thus, 19 studies were included in this research and were
summarized based on: the identiﬁcation of the article, the
database where it was found, the studied population, study
design, patient characteristics, incidence of nephrotoxicity,
intervention (cyclosporine, dosage, routes, usage time) and
nephrotoxicity-related factors.
On reading the texts in full, the articles were evaluated
using the Strengthening the Reporting of Observational Stud-
ies in Epidemiology (STROBE) technique.14 Although this is not
a tool to evaluate the quality of an article’s methodology, it
presents important aspects regarding features of the method-
ology considered relevant for this research, which are: (A)
context: place description, relevant dates including recruiting
time, exposure, follow-up and collected data; (B) participants:
eligibility criteria, selection method of participants; and (C)
data source/measurement: data source and detailed evalua-
tion methods. In cases where data were lacking, the article was
excluded. The data on the articles were saved on a Microsoft
Excel® worksheet and classiﬁed based on the level of scientiﬁc
evidence, according to the Oxford Centre for Evidence Based
Medicine.15,16
Results
Most of the publications were identiﬁed in PubMed (84.2%) and
presented an observational methodological design and non-
probabilistic sample (89.5%) on patients undergoing HSCT,
with follow-ups equal to or greater than 100 days (52.6%). All
the studies presented level 2B scientiﬁc evidence.
The median age of subjects of the studies ranged from 18
to 52 years and the mean age was between 25 and 56.5 years.
There was a predominance of myeloablative therapy (79%),
and a diagnosis of leukemia (100%) or lymphoma (57.9%). More
than half the studies (52.6%) presented the terms ARF or AKI to
deﬁne nephrotoxicity, which are the predominant terms after
2000.
The cyclosporine dose varied from 2.5 to 5 mg/kg/day
by intravenous administration, with a subsequent switch
to peroral administration. The oral dose ranged from 5 to
12.5 mg/kg/day for three to six months. Most of the studies
(89.5%) showed a greater than 30% incidence of nephrotoxicity
and cyclosporine appeared as a risk factor for nephrotox-
icity in around one-third of the studies (31.6%) associated
with amphotericin B and/or aminoglycoside. Cyclosporine
was used as an immunosuppressive agent monotherapy
in 52.6% of the studies. In the others, it was associated
with different immunosuppressants such as methotrexate,
prednisone, cyclophosphamide and mycophenolate mofetil
(Table 1).
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Table 1 – Description of articles included in the systematic review.
Author (year) Study type, follow-up
and sample
Nephrotoxicity
Deﬁnition Incidence
Cyclosporine as a risk factor
Other associated factors
Hows et al. (1983)17 Cohort 4 weeks n = 33 Acute nephrotoxicity –
serum Cr > 200 mol/L
36.4%
Statistically signiﬁcant (p-value < 0.001)
Associated with aminoglycoside
Kennedy et al. (1983)18 RCT 90 days n = 47 Acute kidney toxicity –
serum Cr ≥2× basal
80.0%
Statistically signiﬁcant (p-value < 0.01)
Associated with amphotericin B
Kennedy et al. (1985)19 Cohort 60 days n = 63 Kidney dysfunction – serum
Cr ≥ 2× basal
86.0%
Statistically signiﬁcant (p-value < 0.001)
Associated with amphotericin B
Kone et al. (1988)20 RCT Double blind 100
days n = 82
Kidney dysfunction – serum
Cr elevated
64.0%
Cyclosporine is the cause (descriptive analysis)
Hypertension and associated with hypomagnesemia
Miller et al. (1994)21 Cohort 4 weeks n = 45 Nephrotoxicity – serum
Cr > 2 mg/dL
31.0%
Statistically signiﬁcant (p-value < 0.01)
Associated with amphotericin B
Miralbell et al. (1996)22 Cohort – n = 79 Kidney dysfunction – serum
Cr > 110 mol/L
–
Not  signiﬁcant
Parikh et al. (2002)23 Cohort 1 year n = 88 Kidney dysfunction –
conventional criteria
92.0%
Not  signiﬁcant
Kishi et al. (2005)24 Cohort 28 days n = 35 Kidney dysfunction – CTC 54.3%
Not signiﬁcant
Hingorani et al. (2005)9 Cohort – n = 159 ARF – serum Cr ≥ 2× basal 36.0%
Not signiﬁcant
Caliskan et al. (2006)25 Cohort 100 days n = 47 AKI – Conventional criteria 70.0%
Statistical signiﬁcance (p = 0.04)
Associated with aminoglycoside and amphotericin B
(descriptive analysis)
Kersting et al. (2007)10 Cohort 3 months
n = 363
ARF – conventional criteria 93.4%
Not signiﬁcant
Lopes et al. (2008)26 Cohort 100 days n = 82 AKI – RIFLE 53.6%
Cyclosporine is the cause (descriptive analysis)
Kersting et al. (2008)27 Cohort – n = 150 ARF – conventional criteria 94.0%
Cyclosporine is the cause (descriptive analysis)
Mae et al. (2008)28 Cohort 100 days n = 54 AKI – serum Cr ≥ 2× basal 27.8%
Not signiﬁcant
Pinana et al. (2009)29 Cohort 1 year n = 188 ARF – conventional criteria 52.0%
Cyclosporine is the cause (descriptive analysis)
Saddadi et al. (2010)30 Cohort 180 days
n = 378
AKI – serum Cr ≥ 2× basal 37.6%
Statistical signiﬁcance (p-value < 0.001)
Associated with amphotericin B
Kagoya et al. (2011)31 Cohort 100 days
n = 207
AKI – RIFLE 76.3%
Cyclosporine is the cause (descriptive analysis)
Helal et al. (2011)32 Cohort 1 year n = 101 ARF – serum Cr ≥ 2× basal 57.4%
Not signiﬁcant
Bao et al. (2011)33 Cohort 100 days
n = 143
AKI – RIFLE 48.9%
Not signiﬁcant
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aRCT: randomized clinical trials; Cr: creatinine; CTC: common toxici
injury, failure, loss and end-stage kidney disease.
iscussion
he evidence from this research suggests that cyclosporine
epresents a risk factor for the development of nephrotoxicity
n HSCT recipients,17–19,21,25,30 in the context of continuous
sage and increasing serum levels17,19 of cyclosporine,17–19,34
ith the co-administration of amphotericin B18,19,21,25,30
nd/or aminoglycoside antibiotics.17,25teria; ARF: acute renal failure; AKI: acute kidney injury; RIFLE: risk,
There was a predominance of cohort studies,9,10,17,19,21–33
which were classiﬁed according to their scientiﬁc evidence
as level 2B. In other words, they are trustworthy and good
quality studies; thus, it is highly unlikely that new studies
can show substantial changes regarding effects.15,16 Although
the observational methodological design does not represent
the highest level of scientiﬁc evidence, it brings information
about cyclosporine usage by different patient groups and ana-
lyzes, above all, the impact of long-term immunosuppression,
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proposing important ﬁndings on events of toxicity, especially
those at low frequency that are not typically identiﬁed in clin-
ical trials.
In general, patient follow-ups were greater than or equal
to 100 days.20,23,25,26,28–33 This is expected since these patients
generally present risks for acute complications and mortal-
ity within this time frame. Moreover, the literature suggests
that the ﬁrst 100 days post-transplant is a “cut off” for the
occurrence of nephrotoxicity,6,35 the object of analysis in this
systematic review.
More  than half (52.6%) of the included papers used ARF
or AKI to deﬁne nephrotoxicity. As mentioned, these terms
became predominant after 2000. The variety of terms for
deﬁning nephrotoxicity can be explained by the addition of
different diagnostic criteria in 1980. One criterion of nep-
hrotoxicity that has become common is serum creatinine
level equal to or greater than double the patient’s baseline
value.9,17,19,21,30,32,36
The predominant conditioning regimen was myeloablative
(79%), the intensity of which causes total or almost total bone
marrow cell destruction in the recipient, in general, through
high doses of chemotherapy.37 Patients undergoing myeloab-
lative conditioning, on the whole, presented a mean or median
age under 50 years and the regimen was not an independent
variable for nephrotoxicity.
Almost all studies (89.5%) indicated an incidence of nep-
hrotoxicity of more  than 30%.9,10,17–21,23–27,29–33 In other words,
nearly one-third of patients undergoing HSCT and exposed
to cyclosporine at doses from 5.0 to 12.5 mg/kg/day by oral
administration developed some sort of kidney dysfunction.
Cyclosporine was considered a risk factor for nephrotoxicity
in 31.6% of the investigations.17–19,21,25,30
In the studies which indicated some association between
cyclosporine and nephrotoxicity, synergism between dif-
ferent nephrotoxic agents – cyclosporine, amphotericin
B and/or aminoglycosides – was observed.17–19,21,25,30 The
complex pharmacotherapy in patients undergoing HSCT,
which includes not only a large number of drugs with
interactive potential, but also combinations of agents
with similar adverse reaction proﬁles, enhances the toxic
effects.19,21,25,30,38 In this case, it is well known that
cyclosporine, aminoglycosides and amphotericin B may cause
acute tubular necrosis. This dysfunction can appear in
patients undergoing monotherapy, but, overall, it is worsened
by these combinations (toxic synergism).39
The studies indicate a correlation between nephrotoxicity
and increased serum creatinine levels as well as cyclosporine
level.17,18 One of them clearly demonstrated a correlation
between serum levels of cyclosporine, creatinine and urea (p-
value < 0.001); in one fraction of the sample, the rise in serum
cyclosporine preceded an increase in creatinine. Another risk
factor for acute nephrotoxicity with cyclosporine therapy
was the simultaneous use of aminoglycoside antibiotics (p-
value = 0.01). Cyclosporine levels of less than 400 ng/mL were
not seen to cause serious acute nephrotoxicity.17
Another investigation compared a group of patients who
simultaneously took methotrexate and amphotericin B with
another group concurrently taking cyclosporine and ampho-
tericin B; the group treated with cyclosporine presented a 2 0 1 4;3  6(5):363–368
higher incidence of nephrotoxicity (80%) than the group
treated with methotrexate (19%) (p-value < 0.01).18
The cyclosporine concentrations used were associated
with nephrotoxicity in patients undergoing myeloablative
therapy. The concentrations varied from <150 ng/mL to
>250 ng/mL; furthermore, when patients presented a serum
cyclosporine concentration higher than 250 ng/mL, the devel-
opment of toxicity was faster. These differences related to
cyclosporine concentration were not explained by risk factors
such as age, basal creatinine or concurrent use of nephrotoxic
antibiotics. It was ascertained that the highest mean concen-
tration of cyclosporine was associated with the highest risk for
the development of nephrotoxicity (p-value < 0.001). In addi-
tion, comparing patients who took amphotericin B with those
who had not taken this antifungal, stratiﬁed by cyclosporine
concentration, showed that this drug was a signiﬁcant inde-
pendent risk factor for the development of nephrotoxicity
(p-value < 0.01).19
In allogeneic bone marrow transplant recipients,
cyclosporine represented the most frequent cause of
nephrotoxicity. However, the authors did not observe a
correlation between a short period of elevated cyclosporine
concentration and creatinine clearance over a period of 20
days post-transplant. Nephrotoxicity was more  frequent
with myeloablative allogeneic (91%) than with autologous
transplantation (52%) (p-value = 0.004). Those differences
were attributed to graft-versus-host disease and immuno-
suppressive drug usage, including the toxicity caused by
cyclosporine.25 Comparing kidney dysfunction patients to
those with regular kidney function, a univariate analysis did
not indicate statistically signiﬁcant differences concerning
aminoglycoside or amphotericin B use. Nonetheless, in the
descriptive analysis, amphotericin B contributed to nephro-
toxicity in the group undergoing allogeneic HSCT (5%). In
the group of autologous HSCT, amphotericin B (31%) and
aminoglycoside (8%) use contributed to nephrotoxicity.25
In other studies, authors found that cyclosporine causes
signiﬁcant dose-dependent toxicity (relative risk: 6.17; 95%
conﬁdence: 4.03–9.43; p-value < 0.001). In a descriptive anal-
ysis, aminoglycoside (amikacin) and amphotericin B use were
related to 14.2% and 10.3% of instances of nephrotoxicity,
respectively.30
Some studies considered cyclosporine a cause of nephro-
toxicity based on descriptive analysis.20,25,26,28,31 One of these
studies in particular indicated that cyclosporine was respon-
sible for 21% of grade 2 nephrotoxicity cases.27
The present systematic review was limited due to lack of
detailed information from primary studies, especially about
agent exposure (cyclosporine): biochemical methods used to
dose cyclosporine, the time interval between the last adminis-
tration of cyclosporine and blood collection for serum dosage
of the immunosuppressive drug, the type of biological sam-
ple used to dose the drug, as well as the routes and time of
cyclosporine administration. These data could support further
analysis. The nephrotoxicity valuation parameters, as well as
their deﬁnition, were quite variable. Furthermore, almost one-
third of the studies used descriptive analysis. Hence, in spite
of a wide and systematic search, the possibility of bias should
not be excluded.
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ontribution  to  the  clinical  context
ome of the studies in this systematic review considered that
ephrotoxicity can be prevented by a measure of caution dur-
ng the use of cyclosporine associated with amphotericin B
r aminoglycosides in the form of careful administration and
idney function monitoring.18,20,21 Another study32 recom-
ended that early identiﬁcation of risk factors for AKI, would
void, whenever possible, the exposure of more  susceptible
atients to nephrotoxic drugs during follow-up.29 The risk,
njury, failure, loss, end-stage kidney disease (RIFLE) criteria
ere considered an important tool to stratify HSCT recipients
n relation to risk of death.33,40 In a previous study, these diag-
ostic criteria presented good sensitivity on the evaluation of
ephrotoxicity.
onclusion
he incidence of nephrotoxicity following allogeneic HSCT
anged from 27.8% to 94% with cyclosporine being consid-
red a risk factor for this adverse event in one-third of the
tudies. Some studies, which show an association between
yclosporine and nephrotoxicity, have found synergism with
ther nephrotoxic drugs such as amphotericin B and amino-
lycoside. Systematic monitoring of serum levels of the
dministered drugs and monitoring of the patient’s kidney
unction are essential. In addition, it is indispensable to avoid,
henever possible, the association of cyclosporine with other
ephrotoxic drugs. Furthermore, it is necessary to investigate
ossible risk factors for nephrotoxicity in each HSCT recipient.
inally, considering the importance of cyclosporine to the suc-
ess of HSCT and that nephrotoxicity in HSCT recipients has
een associated with increased mortality, this issue requires
articular attention.
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